CN1310759A - 含治疗和诊断结构域1的β2GP1多肽及其使用方法 - Google Patents

含治疗和诊断结构域1的β2GP1多肽及其使用方法 Download PDF

Info

Publication number
CN1310759A
CN1310759A CN99808415A CN99808415A CN1310759A CN 1310759 A CN1310759 A CN 1310759A CN 99808415 A CN99808415 A CN 99808415A CN 99808415 A CN99808415 A CN 99808415A CN 1310759 A CN1310759 A CN 1310759A
Authority
CN
China
Prior art keywords
polypeptide
domain
β2gpi
gpi
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99808415A
Other languages
English (en)
Chinese (zh)
Inventor
D·M·玛奎斯
G·M·艾沃森
E·J·维克多利亚
D·S·琼斯
M·D·林尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Pharmaceutical Co
Original Assignee
La Jolla Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27376031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1310759(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by La Jolla Pharmaceutical Co filed Critical La Jolla Pharmaceutical Co
Publication of CN1310759A publication Critical patent/CN1310759A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN99808415A 1998-06-09 1999-06-09 含治疗和诊断结构域1的β2GP1多肽及其使用方法 Pending CN1310759A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8865698P 1998-06-09 1998-06-09
US60/088,656 1998-06-09
US10308898P 1998-10-05 1998-10-05
US60/103,088 1998-10-05
US09/328,199 1999-06-08
US09/328,199 US6858210B1 (en) 1998-06-09 1999-06-08 Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same

Publications (1)

Publication Number Publication Date
CN1310759A true CN1310759A (zh) 2001-08-29

Family

ID=27376031

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99808415A Pending CN1310759A (zh) 1998-06-09 1999-06-09 含治疗和诊断结构域1的β2GP1多肽及其使用方法

Country Status (12)

Country Link
US (2) US6858210B1 (enExample)
EP (1) EP1092027B1 (enExample)
JP (1) JP2002517245A (enExample)
KR (1) KR20010052713A (enExample)
CN (1) CN1310759A (enExample)
AT (1) ATE346922T1 (enExample)
AU (1) AU772851B2 (enExample)
CA (1) CA2329942A1 (enExample)
DE (1) DE69934228T2 (enExample)
ES (1) ES2275348T3 (enExample)
PT (1) PT1092027E (enExample)
WO (1) WO1999064595A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102272598A (zh) * 2009-01-02 2011-12-07 福升兴业股份有限公司 用以诊断自体免疫疾病之人工合成肽、方法及试剂盒
CN105801694A (zh) * 2016-05-03 2016-07-27 上海科新生物技术股份有限公司 一种抗心磷脂/β2糖蛋白I复合物的嵌合抗体

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
WO2000075105A1 (en) * 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
CZ2002343A3 (cs) * 1999-07-29 2002-08-14 Epix Medical, Inc. Cílená multimerní zobrazovací činidla s multilokální vazebnou schopností
CN1399562A (zh) * 1999-11-28 2003-02-26 拉卓拉药物公司 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
AU2001268228A1 (en) * 2000-06-08 2001-12-17 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
EP1360207B1 (en) * 2000-12-13 2011-06-22 Bac Ip B.V. Protein arrays of camelid heavy-chain immunoglobulin variable domains
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
JP4800614B2 (ja) 2002-07-19 2011-10-26 ザ ジェネラル ホスピタル コーポレイション オキシム結合体、およびそれらの形成および使用のための方法
AU2003303524A1 (en) * 2002-12-27 2004-07-29 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
DE10310082A1 (de) * 2003-03-07 2004-09-16 Ktb Tumorforschungsgesellschaft Mbh Protein-bindende Doxorubicin-Peptid-Derivate
US20040258683A1 (en) * 2003-03-30 2004-12-23 Linnik Matthew D. Methods of treating and monitoring systemic lupus erythematosus in individuals
CN101146826A (zh) * 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
WO2006113720A2 (en) 2005-04-18 2006-10-26 Bio-Rad Laboratories, Inc. Solid phase immobilization of phospholipids and cofactor proteins via covalent attachment
US20100021379A1 (en) * 2006-06-29 2010-01-28 The Regents Of The University Of California Chemical Antibodies for Immunotherapy and Imaging
US20080015145A1 (en) 2006-07-11 2008-01-17 Maria Gyongyossy-Issa Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions
WO2011163568A1 (en) 2010-06-24 2011-12-29 University Of Kansas Conjugates comprising an n-oxime bond and associated methods
CN105273080A (zh) * 2014-07-14 2016-01-27 于珮 一种还原型β2-糖蛋白Ⅰ的制备方法
US10098960B2 (en) 2015-04-03 2018-10-16 Ucl Business Plc Polymer conjugate
TWI572617B (zh) * 2016-01-20 2017-03-01 國立陽明大學 重組β－醣蛋白胜肽及其於抗腫瘤之應用
US11661447B2 (en) * 2017-08-03 2023-05-30 The Cleveland Clinic Foundation Human β2-glycoprotein I expression
EP4308602A1 (en) * 2021-03-18 2024-01-24 Université de Genève Peptides and use thereof for diagnosing and treating antiphospholipid syndrome
CN115894270B (zh) * 2022-10-10 2024-09-06 深圳市迪克曼生物科技有限公司 一种神经酰胺及其制备方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191668A (en) 1977-02-03 1980-03-04 Scripps Clinic And Research Foundation Induction of immunological tolerance
US5126131A (en) 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US5370871A (en) 1983-01-24 1994-12-06 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4751181A (en) 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
AU633488B2 (en) 1988-04-04 1993-02-04 Northwestern University Binding of immune complexes by modified forms of c-reactive protein
ATE142789T1 (de) 1989-10-19 1996-09-15 Yamasa Shoyu Kk Träger zur bindung von antiphospholipid- antikörpern, diese antikörper verwendender immunotest und kit dafür
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5162515A (en) 1990-01-16 1992-11-10 La Jolla Pharmaceutical Company Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
EP0474849B1 (en) 1990-04-06 1995-09-13 Yamasa Shoyu Co., Ltd. Methods for determining antiphospholipid antibodies
WO1992011029A1 (en) 1990-12-17 1992-07-09 The Johns Hopkins University Suppression of immune responses with oligomeric forms of antigen of controlled chemistry
CA2073846C (en) 1991-07-15 2007-09-18 David S. Jones Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides
JP2886983B2 (ja) 1992-02-05 1999-04-26 ヤマサ醤油株式会社 固相試薬およびそれを用いた抗体の測定法
FR2701263B1 (fr) 1993-02-09 1995-04-21 Elie Stefas Procédé d'obtention d'une composition aqueuse protéinique, composition correspondante, glycoprotéine contenue et son utilisation pour la stabilisation de l'albumine et la détection ou le dosage d'anticorps.
ATE359830T1 (de) 1993-09-08 2007-05-15 Jolla Pharma Chemisch definierten nicht-polymer wertigen plattformmolokülen und ihren konjugaten
WO1995014231A1 (en) 1993-11-16 1995-05-26 Yamasa Corporation Method of assaying antiphospholipid antibody and kit therefor
FR2722991B1 (fr) 1994-08-01 1996-10-11 Orstom Utilisation de la beta2-glycoproteine i sous au moins une de ses formes comme agent anti-infectueux et composition pharmaceutique corrrespondante
JPH08333390A (ja) 1995-04-07 1996-12-17 Hoechst Japan Ltd ペプチド及びそれからなる自己免疫疾患治療剤
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5780319A (en) 1996-04-19 1998-07-14 Pasteur Sanofi Diagnostics Immunoassays to detect antiphospholipid antibodies
EP0954531A1 (en) 1996-06-06 1999-11-10 Lajolla Pharmaceutical Company aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
DE19637770A1 (de) 1996-09-16 1998-03-19 Koenig & Bauer Albert Ag Verfahren und Anlage zum automatischen Zu- und Abführen von Rollen
CA2271784A1 (en) 1996-11-12 1998-05-22 City Of Hope Immuno-reactive peptide ctl epitopes of human cytomegalovirus
GB9805477D0 (en) 1998-03-13 1998-05-13 Oxford Glycosciences Limited Methods and compositions for diagnosis of rheumatoid arthritis
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
IL125262A0 (en) 1998-07-07 1999-03-12 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
IL126447A (en) 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
JP2002542819A (ja) 1999-05-04 2002-12-17 ゲネトール ゲゼルシャフト ミット ベシュレンクテル ハフツング 特異的免疫反応の低減方法
WO2000075105A1 (en) 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
AUPQ272699A0 (en) 1999-09-09 1999-09-30 Unisearch Limited Use of beta2GPI in diagnostic tests for autoimmune diseases
CN1399562A (zh) 1999-11-28 2003-02-26 拉卓拉药物公司 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
US20010051351A1 (en) 2000-03-27 2001-12-13 Racis Stanley Paul Antigen-specific immune complex-based enzyme-linked immunosorbent assay
US20020150898A1 (en) 2000-04-18 2002-10-17 Tang Y. Tom Novel nucleic acids and polypeptides
AU2001263006A1 (en) 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001268228A1 (en) 2000-06-08 2001-12-17 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
DE10048417A1 (de) 2000-09-29 2002-04-11 Roche Diagnostics Gmbh Verbindungen mit verzweigtem Linker

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102272598A (zh) * 2009-01-02 2011-12-07 福升兴业股份有限公司 用以诊断自体免疫疾病之人工合成肽、方法及试剂盒
CN102272598B (zh) * 2009-01-02 2014-06-18 福升兴业股份有限公司 用以诊断自体免疫疾病之人工合成肽及试剂盒
CN105801694A (zh) * 2016-05-03 2016-07-27 上海科新生物技术股份有限公司 一种抗心磷脂/β2糖蛋白I复合物的嵌合抗体

Also Published As

Publication number Publication date
DE69934228T2 (de) 2007-10-04
WO1999064595A9 (en) 2000-09-08
ES2275348T3 (es) 2007-06-01
ATE346922T1 (de) 2006-12-15
AU772851B2 (en) 2004-05-06
PT1092027E (pt) 2007-02-28
DE69934228D1 (de) 2007-01-11
KR20010052713A (ko) 2001-06-25
US6858210B1 (en) 2005-02-22
EP1092027A1 (en) 2001-04-18
US20050004351A1 (en) 2005-01-06
WO1999064595A1 (en) 1999-12-16
CA2329942A1 (en) 1999-12-16
JP2002517245A (ja) 2002-06-18
AU4339599A (en) 1999-12-30
EP1092027B1 (en) 2006-11-29

Similar Documents

Publication Publication Date Title
CN1310759A (zh) 含治疗和诊断结构域1的β2GP1多肽及其使用方法
US10556943B2 (en) HLA-DR binding peptides and their uses
CN1768076A (zh) 淀粉样β(1－42)蛋白寡聚体、其衍生物及抗体、其制备方法和用途
CN1203087C (zh) 因子VIIa抑制剂
CN1192153A (zh) aPL免疫反应性肽和其缀合物以及治疗aPL抗体-介导的疾病的方法
CN1646559A (zh) 治疗阿尔茨海默氏病的免疫学方法及组合物
CN101043901A (zh) 预防和治疗阿尔茨海默病的方法
CN1319987C (zh) γ－分泌酶抑制剂
CN1867581A (zh) Il－21衍生物
CN101039953A (zh) 治疗和诊断剂
CN1227359C (zh) 负调节抗性c3转化酶
CN1268973A (zh) β－淀粉样肽结合蛋白及其编码聚核苷酸
CN1492926A (zh) 神经丝蛋白的优选区段及其使用方法
CN1950394A (zh) 在受试者中抑制免疫复合物形成的方法
HK1039156A (en) THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME
AU2004201699A1 (en) Therapeutic and diagnostic domain 1 Beta2GPI polypeptides and methods of using same
CN1164614C (zh) 记忆清除蛋白及其应用
CN1225015A (zh) aPL免疫反应性肽、其缀合物以及aPL抗体介导的疾病的治疗方法
HK1104228A (en) Method for preventing and treating alzheimer's disease
CN1302875A (zh) 人夏科－莱登晶体5及其编码序列,以及制法和用途
CN1774449A (zh) Memapsin2的抑制剂及其用法
CN1829526A (zh) 可溶性clca－1及clca－1的拮抗剂
CN1281044A (zh) 一种人翻译起始因子蛋白及其编码序列

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1039156

Country of ref document: HK